- TV Footage
- Integrated Annual Reports
- Quarterly Reports
- Bayer Magazine
- BEENOW Magazine
- Farming’s Future Magazine
- research Magazine
- technology solutions Magazine
- From Molecules to Medicine
- From Molecules to Veterinary Medicines Brochure
- Integrated Weed Management
- Names | Figures | Facts
- Transfers of Value to Physicians Brochure
- Newsletter Overview
- Social Media
- Background Information
- Media Contact
Leverkusen, September 7, 2017 – Bayer is once again included in the Dow Jones Sustainability World Index (DJSI World). The company is thereby listed in this sustainability index for the 18th time in succession since its inception in 1999, thus confirming its leading international standing with respect to sustainable business practices in the pharmaceutical and chemical industry. The DJSI World serves as a guide to institutional investors who place particular value on sustainability for their investment strategy.
“We are delighted by our renewed listing in this renowned sustainability index,” said Dr. Hartmut Klusik, member of the Bayer Board of Management responsible for Human Resources, Technology and Sustainability. “Sustainability is a core element of our corporate strategy. We continually endeavor to integrate sustainability aspects into our daily work routines to safeguard Bayer's long-term success and ensure that our activities are beneficial to society,” added Dr. Klusik.
The Swiss rating agency RobecoSAM assessed more than 2,000 of the world’s largest listed companies on behalf of the index provider S&P Dow Jones Indices according to the “best-in-class” principle: the DJSI World lists the top 10 percent of companies in a particular sector on the basis of an extensive set of economic, ecological, ethical and social criteria. In its sector, Bayer was rated particularly highly in the areas of integrated reporting as well as staff development, respect of human rights and supplier management among others.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.